BACKGROUND {#sec1-1}
==========

Since the development of percutaneous neurolysis in 1914 by Kappis,[@ref1] many studies have reported about the most efficacious method of celiac plexus neurolysis (CPN). Meanwhile, various methods and options of CPN indicate some controversy and a lack of significant progress. In this multicenter randomized controlled trial, Doi *et al*.[@ref2] compared the effectiveness of novel endoscopic ultrasound (EUS)-guided celiac ganglia neurolysis (CGN) with conventional EUS-guided CPN (EUS-CPN). The CGN (*n* = 34) and CPN (*n* = 34) groups were well-randomized in terms of the characteristics of patients and pain score. The visualization of celiac ganglia was available in 88% of CGN group, thus 4 patients in whom the ganglia could not be visualized were treated with EUS-CPN. The procedure was successful in all patients allocated to CPN. The primary endpoint was the difference in treatment response rate between CGN and CPN group at post-procedural day 7 measuring pain intensity using a numeric pain rating scale, ranging from 0 (no pain) to 10 (worst pain). The results demonstrated a higher proportion of patients in CGN group showed a decrease in pain intensity to ≤3 on day 7 compared with CPN by intention-to-treat analysis (73.5% *vs*. 45.5%, *P* = 0.026). The complete response, which was defined as a decrease in pain to ≤1 was also higher with CGN than CPN (50.0% *vs*. 18.2%, *P* = 0.010). Actual performance of EUS-CGN was the only statistically significant predictive factor for pain relief. The incidence of complications was similar in both groups. The authors concluded that EUS-CGN is significantly superior to conventional EUS-CPN in cancer pain relief.

COMMENT {#sec1-2}
=======

When proving the efficacy of a new technology, intention-to-treat analysis should be favored. This study was designed to evaluate the superiority of CGN over CPN, and had the strength due to its intention-to-treat approach. Moreover, the authors analyzed with the per-protocol approach and it showed competitive results. The visualization rate of celiac ganglia was also in consistent with previous report.[@ref3] However, it is questionable that injection to the only visible celiac ganglia is effective for pain relief. Celiac ganglia vary in number around celiac trunk and superior mesenteric artery.[@ref4] A mean of 2.9 ganglia were visualized and 3.9 punctures for ethanol injection was performed in this study. Although every celiac ganglion was not visualized and injected, the spilled ethanol during CGN may affect adjacent celiac plexus and ganglia. The authors mentioned that 15 patients (44.1%) in EUS-CGN group showed bilateral spread of ethanol on post-procedural computed tomography. However, it is impressive that EUS-CGN was superior to EUS-CPN despite the less and asymmetric injection of ethanol.

Although the present study attempted to prove the effectiveness of EUS-CGN over EUS-CPN, the results and conclusion must be viewed cautiously given the methodological limitations. The overall success rate of pain relief with EUS-CPN was 45.5% (15/33) at 7 days in this study. This rate seems to be lower than that of other reports for conventional CPN. The published response rate of EUS-CPN has been reported to be about 80%.[@ref5] The poor response rate was probably due to the differences in evaluation criteria and lack of standardized pain assessment tools as mentioned. Furthermore, the low response rate of conventional EUS-CPN may be associated with the "central method CPN" applied in this study. Sahai *et al*.[@ref6] reported that the "bilateral CPN" was more effective than "central CPN". Interestingly, the short-term (day 7) response rates of "central CPN" and "bilateral CPN" (45.9% *vs*. 70.4%, *P* = 0.0016) were very similar to those of study which compared EUS-CPN and EUS-CGN. The definition of treatment response was also similar between the two studies. Therefore, prospective randomized study comparing CGN with "bilateral CPN" may be warranted to verify the effectiveness of CGN over CPN.

Another point is that there was no control for narcotics and other treatment which could have affected the pain scoring. Thus, this study was not independent of drugs and other pain control. The change of required narcotics after the procedure was not mentioned, either. Besides that, there was no description about the location of tumor in 4 patients who failed EUS-CGN initially. The location of tumor is important since it is more difficult to find the celiac ganglia when the tumor is located in the body or tail of pancreas. Finally, the authors evaluated the short-term effects of pain relief. In addition, the duration of effect among patients who showed response after the procedure was investigated. However, they did not measure long-term response rates among whole patients. The results of long-term pain relief as well as a short-term response are also required.

In summary, Doi *et al*.[@ref2] provide an important contribution to the new technology of celiac neurolysis. These findings are useful to clinicians and would accelerate the development of EUS-guided procedures.
